GlassScriptPhysician profile
Richard Eugene Frye
NPI 1891730461
$4,092.55
in general payments reported to CMS, 2019-2025
13 companies · $37.11 in 2025
The $37.11 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $22.19 · 2021: $27.06 · 2022: $3,803 · 2023: $24.71 · 2025: $37.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $2,003.00 | 2022 | |
| Acadia Pharmaceuticals INC | $1,800.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $85.64 | 2019 | |
| Ucb, INC. | $68.39 | 2020-2023 | Briviact |
| Neurelis, INC. | $37.11 | 2025 | Valtoco |
| Mallinckrodt Enterprises LLC | $17.99 | 2019 | |
| Ptc Therapeutics, INC. | $17.56 | 2019 | |
| Eisai INC. | $16.60 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.06 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.79 | 2019 | |
| Lilly USA, LLC | $11.84 | 2019 | |
| Travere Therapeutics, INC. | $5.57 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Frye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.